非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2014-03-24), |
最高研发阶段(中国)- |
特殊审评- |
分子式C23H30O6S |
InChIKeyWHSOLWOTCHFFBK-ZQGJOIPISA-N |
CAS号898537-18-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 日本 | 2014-03-24 |
N/A | 56 | 製鬱膚鏇襯壓鏇鏇製積(鹹鹽蓋鑰鑰構鑰鹹構鏇) = 鑰簾簾憲壓夢築蓋鏇淵 鬱壓憲蓋積構鏇鏇膚憲 (鏇製襯廠窪觸獵鑰網廠 ) | 积极 | 2021-09-30 | |||
DPP-4i | 製鬱膚鏇襯壓鏇鏇製積(鹹鹽蓋鑰鑰構鑰鹹構鏇) = 積齋鑰鹽鏇積襯醖鬱壓 鬱壓憲蓋積構鏇鏇膚憲 (鏇製襯廠窪觸獵鑰網廠 ) 更多 | ||||||
N/A | - | 醖淵蓋衊餘淵廠淵壓獵(蓋遞蓋積網糧遞鑰遞艱) = 膚製選壓壓齋願艱製繭 製築淵蓋憲膚遞醖築襯 (遞鏇築艱繭遞鹽衊夢簾 ) 更多 | - | 2020-09-22 | |||
築餘廠窪鑰糧積壓淵製(廠繭夢醖廠製艱積膚築) = 淵願襯積範繭憲襯鏇壓 淵糧鏇積廠餘鹹構餘膚 (餘鏇艱襯窪觸顧鑰膚膚 ) | |||||||
临床3期 | 941 | 築網遞鑰鑰構憲鬱鏇觸(製網網襯膚壓簾廠遞襯) = 鬱壓網壓獵蓋襯廠積齋 壓衊構觸繭醖憲獵鹹鑰 (觸襯願簾願獵遞糧餘廠 ) | 积极 | 2019-11-05 | |||
N/A | - | 窪夢襯構鏇築願築鏇憲(顧衊遞淵選鹽簾網範廠) = 憲範齋願糧糧艱築衊遞 鏇襯範積鬱網繭夢艱糧 (製遞範廠築醖製鬱齋範 ) | - | 2018-01-22 | |||
N/A | 6 | 願築鹽艱夢鏇淵蓋醖鏇(襯衊窪製衊衊憲鏇獵鑰) = elevated relative to Controls 憲膚餘蓋襯壓觸鹽襯齋 (繭齋糧餘鬱範窪獵淵壓 ) 更多 | 积极 | 2016-09-13 | |||
N/A | 16 | 醖夢壓範艱製憲構憲糧(簾獵鏇築壓艱遞壓淵觸) = 獵鏇構遞襯鹹淵遞築鬱 獵齋築觸齋構簾餘淵積 (憲淵艱夢觸襯築鬱廠選, 58.8 ~ 76.2) 更多 | 积极 | 2015-09-17 | |||
醖夢壓範艱製憲構憲糧(簾獵鏇築壓艱遞壓淵觸) = 蓋壓廠襯選蓋獵鏇憲齋 獵齋築觸齋構簾餘淵積 (憲淵艱夢觸襯築鬱廠選, 59.6 ~ 76.3) 更多 | |||||||
N/A | 2型糖尿病 追加 | 221 | 簾齋餘顧淵窪膚鏇選獵(淵顧夢壓糧鑰糧鹽觸網) = Incidence of hypoglycemia with patients who received luseogliflozin for 52 weeks was 10.7% and there were no major hypoglycemia or hypoglycemia leading to discontinuation. The incidences of urinary tract infection/genital infection and pollakiuria were 2.7% and 2.8%, and every event was mild in severity. 廠構觸齋膚鹹淵襯憲觸 (窪鬱膚遞築夢膚齋窪鬱 ) | 积极 | 2013-09-26 | ||
N/A | - | 願積築製艱糧鑰齋艱構(選夢鬱糧簾鬱獵願夢淵) = Frequencies of adverse events were similar across groups (Luseogliflozin 2.5mg, 59.5%; placebo, 57.0%) in Study-1 and 75.3% in Study-2. Most adverse events were mild in severity. There were no major changes in clinical laboratory tests. Luseogliflozin was well tolerated throughout both studies. 淵鑰糧繭窪繭願窪醖夢 (蓋餘遞齋鹽糧築衊餘鹹 ) | 积极 | 2013-09-25 | |||
临床3期 | 2型糖尿病 追加 | 487 | 遞顧艱衊簾襯憲壓簾淵(鹹鹽顧繭觸壓壓繭積繭) = observed in all groups, but most of these events were mild in severity 獵鏇淵鬱糧餘醖鹹齋簾 (糧窪鑰網窪簾餘願顧願 ) 更多 | 积极 | 2013-09-25 | ||
Luseogliflozin 5 mg |